WP1130 also increases the cytotoxic effects of cisplatin partly via its inhibitory effect on USP9X in ER- breast cancer cells, suggesting combination therapy with WP1130 may be an efficient method for patients with ER- breast cancer [106]. Here, USP9X is linked to breast cancer.